Cambrex expands analytical capabilities12 Dec 2018
The $1 million investment will assist in getting new products to commercial launch faster.
Cambrex is investing $1 million at its High Point, NC site to fit out 1,300 sq ft of analytical laboratory space and plans to hire nine chemical research and development scientists, as well as six analytical research and development scientists pursuant to this project. This investment follows the new $3.2 million, 11,000 sq ft analytical laboratory, completed in April 2018.
The expansion and fit out, which will include the installation of an additional 10 ultra-performance liquid chromatography (UPLC) instruments, is set to be completed by year-end 2018.
“Cambrex is seeing a significant increase in new projects, resulting in increased demand for analytical development capabilities within the Cambrex organization,” commented Brian Swierenga, VP, Operations and Site Director for Cambrex High Point. He added: “This further expansion will not only increase Cambrex’s internal analytical capabilities and capacity, but will assist in getting new products to commercial launch faster.”
At the facility, Cambrex produces complex APIs and intermediates requiring multi-step synthetic processes in batch sizes from milligrams to 100 kg to support clinical trials from Phase I to Phase III. The site is licensed with the US Drug Enforcement Administration (DEA) to manufacture Schedule II to Schedule V controlled substances. The acquisition enhanced Cambrex’s portfolio of small molecule API services and complements its large-scale, multi-purpose manufacturing facilities in the US and Europe.
This latest expansion at the 35,000-sq ft facility brings the investment at the site to over $9 million since the acquisition of PhamaCore by Cambrex in 2016.
Follicum files patent application for new topical formulation for hair loss
30 Apr 2019
Using easy-to-apply cream instead of direct scalp injection would extend patent protection by 8 years.Read more
Hovione Technology acquires global rights to new pulmonary inhaler device
15 Apr 2019
The Papillon DPI is a single-part, blister-based, reusable inhaler, suitable for both chronic and acute treatments.Read more
Isotype-specific secondary antibodies for improved signal detection
10 Apr 2019
Offers an alternative to cross-adsorbed secondary antibodies when absolute specificity is required.Read more
Sterling Pharma to acquire CiVentiChem in the US
9 Apr 2019
The acquisition will enhance the CDMO's chemistry development capabilities to support pre-clinical and early phase clinical supply.Read more
Catalent expands OptiMelt hot melt extrusion capabilities
4 Apr 2019
The investment includes the addition of equipment to enhance development capabilities for preclinical and early clinical phase development, as well as adding downstream processing technologies to support HME formulations.Read more
'Drugs from bugs' joint venture
4 Apr 2019
Lonza and Chr. Hansen create a strategic joint venture to become the partner of choice for developing and manufacturing live biotherapeutic products for pharma and biotech customers.Read more
Curcumin and pomegrantes - new hope for Alzheimer’s prevention?
3 Apr 2019
New research at University of Warwick will test how curcumin kick-starts the brain’s cleansing of damaging plaques and cells.Read more
MedPharm's appointment with Destiny
28 Mar 2019
Global contract provider to develop new XF-platform drug formulations for the treatment of a number of topically treated infections, including diabetic foot ulcers and ophthalmic infections.Read more
Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy
13 Mar 2019
Event for experts from academia and industry, including talks, live demo sessions, and panel discussion.Read more
Envigo launches PATHWAY to enable FIH clinical trials
11 Mar 2019
PATHWAY manages the complexity of the entire safety assessment process on behalf of the company’s pharmaceutical and biotechnology customers.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation